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Zika virus (ZIKV) infection has been recognized since 1947, but just recently it 
became a worldwide major public health problem. The most common features 
of ZIKV infection are fever, cutaneous rash, arthralgia, and conjunctivitis but 
most affected patients with the clinical disease present with only mild 
symptoms. However, severe neurologic complications have been described: 
there is an occasional association with Guillain-Barre syndrome, and emerging 
data indicate an association between vertical transmission of ZIKV infection and 
microcephaly but no specific orofacial manifestations have yet been reported. 
ZIKV is present in body fluids and has also been demonstrated in the saliva, but 
there is as yet no reliable evidence to support ZIKV transmission via this 
pathway. Transmission in oral healthcare should be effectively prevented using 
standard infection control measures. There are currently no specific treatments 
for ZIKA virus disease and no vaccines available, so prevention of ZIKV is 





Infection with Zika virus (ZIKV), a flavivirus was a neglected tropical disease 
with limited geographic spread until its major epidemic potential was highlighted 
during a large-scale outbreak in the Pacific Island of Yap in 2007 (Duffy et al., 
2009). Several species of Aedes spp. mosquitoes have been incriminated as 
vectors of ZIKV, including Aedes aegypti. 
The most common features of ZIKV clinical infection are fever, cutaneous rash, 
arthralgia, and conjunctivitis. ZIKV had not been known to cause severe 
disease or hospitalisations until an outbreak in French Polynesia in 2013–2014, 
when there were reports of neurological and auto-immune complications, such 
as Guillain-Barre syndrome (GBS) (Cao-Lormeau et al., 2016). Brazil declared 
a national public-health emergency in November 2015 after officials there noted 
a sharp increase in cases of microcephaly in newborns. Recent data also 
suggest an association between ZIKV infection and meningoencephalitis 
(Carteaux et al., 2016).  
Faced with this emerging scenario, governments and public health authorities 
are establishing strategies to control ZIKV infection and limit its potential 
complications. To increase the awareness of this health problem, the World 
Health Organisation (WHO) has recently made available an app, “WHO Zika 
App”, which provides for health care workers, the latest information on ZIKV 
(http://www.who.int/risk-communication/zika-virus/app/en/).  
 
Epidemiology of ZIKV 
ZIKV was first isolated from a sentinel rhesus monkey placed in the Ugandan 
Zika Forest in 1947. A second isolation from the mosquito Aedes africanus 
followed at the same site in 1948. Since then, sporadic ZIKV isolations have 
been made from humans and a variety of mosquito species both in Africa and 
Asia, supported by seroprevalence studies in humans and animals (Haddow et 
al., 2012). It is possible that ZIKV may have undergone recombination in nature 
and, after emerging in Uganda, it spread to West Africa and Asia, without any 
clear preference for any host or vector species (Faye et al., 2014). 
Nevertheless, it has been shown the various ZIKV strains are genetically very 
similar to each other with strong conservation overall (Haddow et al., 2012).  
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The first human ZIKV infection was reported in 1957, and the first large Zika 
outbreak in humans was in 2007, on the Pacific Island of Yap, Micronesia, 
where nearly 73% of people were infected. However, between 2013-14, ZIKV 
outbreaks then were reported in other Pacific Islands of French Polynesia, 
Easter Island, Cooks Island and New Caledonia (Kindhauser et al., 2016). In 
April 2015, researchers at the Federal University of Bahia in Brazil reported the 
identification of ZIKV RNA in 8 out of 25 Brazilian samples tested. This was 
then followed by reports of ZIKV in Camaçari (BA state [Bahia]), Natal (Rio 
Grande do Norte state), São Paulo (SP) state and Sumaré region (SP). 
Currently, ZIKV is widespread particularly in Latin America but since January 
2007,  66 countries worldwide have reported outbreaks of ZIKV disease and as 
of 11 May 2016, 58 countries and territories report continuing mosquito-borne 
transmission (http://www.who.int/emergencies/zika-virus/situation-report/12-
may-2016/en/). 
However, the true incidence of ZIKV infection is unknown, as symptoms may be 
subclinical, unrecognised or mimic those of other arboviral flavovirus diseases 
such as chikungunya and dengue and there has been a lack of a widely 
available inexpensive, simple, reliable laboratory diagnostic test for ZIKA. 
Given the worldwide spread of chikungunya and dengue, associated with 
urbanization and globalization, there is a potential risk of outbreaks of ZIKV 
infection in urban settings in any part of the world where the mosquito vectors 
are present or become established in future. Figure 1 highlights the countries 
affected by ZIKV and the year of the first described case in each place. 
 
Modes of transmission of ZIKV 
The ZIKV natural transmission cycle in urban and suburban environments is 
human–mosquito–human, involving mosquitoes of especially Aedes species. 
Aedes aegypti and Aedes albopictus are responsible for the large majority of 
ZIKV outbreaks investigated. 
According to the latest WHO situation report (11 May 2016), person-to-person 
transmission of ZIKV has been documented in 9 countries, probably via a 
sexual route. The perinatal transmission has also been described, and the 
potential for transfusion-transmitted infection exists (Musso et al., 2014). 
Besnard et al. (2014) described the clinical and laboratory features of two 
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mothers and their newborns who had ZIKV infection confirmed by ZIKV RNA 
detection in serum collected four days post-partum. ZIKV particles have been 
demonstrated in breast milk, although to date, transmission via this route has 
not been reported (Dupont-Rouzeyrol et al., 2016). Infectious ZIKV has been 
detected in semen and transmission by heterosexual and homosexual routes 
has been demonstrated, reinforcing the need of using condoms especially for 
sexual activities during pregnancy (D’Ortenzio 2016). ZIKV RNA has also been 
detected in urine at higher loads and with a longer duration than in serum, as 
well as being found in amniotic fluid, placental or foetal tissues in several cases 
of nervous system malformations, including microcephaly (Dupont-Rouzayrol et 
al., 2015). ZIKV has been demonstrated in cell culture from the saliva of an 
Italian patient who had visited the Dominican Republic (Barzon 2016), and a 
monkey bite has been proposed as a plausible route of transmission, and ZIKV 
RNA has been detected in saliva from patients with Zika fever (Musso et al., 
2015) but there as yet no reliable evidence to support ZIKV transmission 
through human saliva (Siqueira et al, 2016). In addition, the most updated data 
(April 26) regarding countries with confirmed local transmission are reported in 
table 2.  
 
Clinical and laboratory features of ZIKV disease 
ZIKV infection is believed to be asymptomatic or mildly symptomatic in most 
cases. The incubation period ranges from 2 to 7 days. Symptoms can last for up 
to a week, with a clinical presentation similar to that of other arbovirus infections 
such as chikungunya and dengue. The most common signs and symptoms of 
ZIKV infection are rash, self-limiting acute fever, arthralgia, myalgia, headache, 
and conjunctivitis. The rash is most often maculopapular and pruritic. 
Haemorrhagic signs are uncommon (Duffy et al., 2009). In contrast to acute 
dengue cases, ZIKV patients only rarely present mild thrombocytopenia and 
leucopenia, and metabolic dysfunction is not commonly observed  (Kutsuna et 
al., 2014).  
Occasionally, sore throat, cough, vomiting, diarrhoea and aphthous-like oral 
ulcers have been reported (Tappe et al., 2014; Foy et al., 2011). The oral ulcers 
in ZIKV have not been well documented in reports although they have been 
noted to appear on the lip mucosa (Foy et al., 2011) and apparently was a 
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common presenting complaint in the French Polynesian outbreak of 2013 
(http://www.npr.org/sections/goatsandsoda/2016/02/09/466152313/zika-in-
french-polynesia-it-struck-hard-in-2013-then-disappeared). There are very 
limited data indicating additional oral changes associated with ZIKV illness 
(Scully and Robinson 2016; Shakib 2016). 
Risk groups for ZIKV infection include patients living in or returning from any of 
the many ZIKV affected areas, presenting with a fever or ‘dengue-like’ 
syndrome and testing negative for DENV. In this context, symptomatic pregnant 
women and their newborns should be tested for ZIKV (Besnard et al., 2014).  
ZIKV diagnosis can be based on multiple tests.  Serology through detection of 
IgM against ZIKV by ELISA (Enzyme Linked Immuno-Sorbent Assay) is a cost-
effective option and cross-reacting antibodies with other flaviviruses can be 
differentiated by the plaque reduction neutralisation test for Zika antibodies. 
Nevertheless, IgM ELISA is expected to be positive by the end of the first week 
of infection and few laboratories have this facility (http://www.cdc.gov/zika/hc-
providers/diagnostic.html). Laboratory confirmation of ZIKV infection is based 
mostly on detection of virus RNA in serum, using real-time Reverse 
Transcription Polymerase Chain Reaction (rRT-PCR). Urine samples may be 
used in less than 14 days of symptomatic disease for ZIKV RNA detection.  
 
Disease associations of ZIKV 
Microcephaly and Birth Defects (Congenital Zika Syndrome) 
Microcephaly refers to a small head size (below -2 standard deviations) for the 
gestational age and sex.  To date, microcephaly, and other foetal malformations 
potentially associated with Zika virus infection or suggestive of congenital 
infection, have been reported in seven countries or territories. Two cases, each 
linked to a stay in Brazil, were detected in Slovenia and the USA. One 
additional case, linked to a stay in Mexico, Guatemala and Belize, was in a 
pregnant woman in the USA (http://www.who.int/emergencies/zika-
virus/situation-report/12-may-2016/en/).  
The microcephaly clusters in Brazil have captured the attention of WHO and the 
world’s media, given that 98% of cases have been reported from there.  During 
late 2015, the Brazilian Ministry of Health began reporting an unusual increase 
in cases of microcephaly, first, in Pernambuco state, in north-eastern Brazil, 
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then in 3 other states. On Nov 11th 2015, Brazil declared a national public health 
emergency and began undertaking clinical, laboratory, and ultrasound analysis 
of affected newborn babies and their mothers.  Data indicate that From 22nd 
October 2015 to 9th April 2016, 7015 suspected cases of microcephaly (or other 
neurological abnormalities of newborns) have been reported. Among these, 
1,113 have been confirmed ZIKA, 3,836 cases are still under investigation, and 
2066 cases discounted, either because they did not fit standardised criteria for 
microcephaly or were attributable to other causes (Ministry of Health, Brazil 
[http://www.paho.org/hq/index.php?option=com_content&view=article&id=1159
9&Itemid=41691&lang=en]). Although the accuracy of microcephaly data has 
been questioned in the past (Butler, 2015), with enhanced surveillance, 
standardised and consistent case definitions, protocols and guidelines, current 
emerging data reflects more accurate reporting 
(http://www.paho.org/hq/index.php?option=com_content&view=article&id=1111
7&Itemid=41532&lang=en).  
Separately, a prospective study of ZIKV infected pregnant women has 
demonstrated high rates of foetal abnormalities on ultrasonography with 
adverse outcomes including foetal loss and microcephaly (Brasil et al., 2016). 
None of the ZIKV-negative women had any foetal abnormalities. There are 
shared peptides between ZIKV proteins and altered human proteins in 
microcephaly and brain calcifications, strengthening the link between ZIKV and 
neurological complications (Lucchese and Kanduc, 2016). 
Furthermore, ZIKV abrogates neurogenesis, and its demonstration in foetal 
brain tissue, strengthens the link between ZIKV infection and microcephaly 
(Garcez et al., 2016), as does the fact that dengue virus targets only human 
brain cells. Besides microcephaly, other abnormalities reported with congenital 
ZIKV infection include low birth weight, redundant scalp skin, facial 
disproportionality, swallowing defects, hypertonia/spasticity, 
tremors/convulsions and hearing defects (Miranda-Filho Dde et al., 2016). 
Arthrogryposis, a rare disease characterised by a severe deficiency in the joints 
(Oliveira-Melo et al., 2016) and ocular abnormalities (optic nerve hypoplasia, 
chorioretinal atrophy, focal pigment mottling of the retina) have also been 
described in ZIKA affected newborns (de Paula Freitas et al., 2016). It is 
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unclear as to how the craniofacial and other defects noted may evolve and 
impact the growing child in future years. 
A recent review assessing available data on the basis of both the Shepard’s 
Criteria for Proof of Teratogenicity in Humans (see Table 1) and the Bredford 
Hill Criteria, concluded that current evidence is sufficient to establish ZIKV as a 
teratogen (Rasmussen et al. 2016).  
 
Guillain-Barre syndrome (GBS) 
GBS is an acute paralytic peripheral neuropathy characterized by nerve 
inflammation and demyelination probably secondary to the action of antibodies 
against myelin antigens. GBS is often triggered by a viral infection, including 
dengue. GBS can be a life-threatening disorder with a mortality of 3-7%, mainly 
from pulmonary complications or respiratory failure (Willison 2016). As of April 
2016, 13 countries had reported an increase in GBS cases in ZIKV infection 
(WHO, 2016).  ZIKV-associated GBS was first noted in French Polynesia in 
2013-14, where 42 patients (72% male) were diagnosed with GBS, of whom 41 
(98%) had IgM or IgG antibodies against ZIKV. All GBS cases had neutralising 
antibodies to ZIKV and 88% had symptomatic ZIKV infection before the onset of 
neurological symptoms, supporting a causal link between ZIKV and GBS. 
Electrophysiological findings were compatible with the acute motor axonal 
neuropathy subtype of GBS. Although 38% of patients were admitted to 
intensive care for swallowing difficulties or respiratory assistance, no deaths 
were reported (Cao-Lormeau et al., 2016).  
Research has demonstrated the existence of extensive peptide sharing 
between ZIKV and altered human proteins related to demyelination and axonal 
neuropathies, typical of GBS (Lucchese and Kanduc, 2016). Immune cross -
reactivity (molecular mimicry) leading to autoimmune processes may thus 
predispose to GBS.  
 
Prevention of ZIKV transmission 
Like many vector-borne diseases, the absence of vaccines and specific 
treatment against ZIKV means prevention and control are largely based on 
vector control and standard control of cross-infection methods. Prevention 
against mosquito bites (particularly daytime bites) is best offered by leaving skin 
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as little exposed and covered with mosquito repellents. Icaridin provides up to 
10 hours of protection and has been the first option for adults and pregnant 
women. Repellents are not recommended for use on babies younger than 2 
months old; oil of lemon eucalyptus or para-menthane-diol repellents are not 
recommended for children younger than 3 years old.  
Other prevention measures, include the elimination of mosquito breeding sites, 
limiting travel to affected areas, avoiding unprotected sex and taking 
precautions to avoid the risk of transfusion-transmission of ZIKV, for example by 
deferring potential blood donors returning from affected areas 
(http://www.cdc.gov/mmwr/volumes/65/wr/mm6512e3.htm, 
http://www.cdc.gov/zika/transmission/blood-transfusion.html).  
The Butantan Institute in San Paulo, Brazil along with two other laboratories 
connected to the Brazil health ministry, and the U.S. government is also working 
on vaccines. One approach is a DNA-based vaccine involving a newer 
technique that injects a piece of the viral DNA rather than a protein fragment of 
the virus to stimulate the immune system. The other is known as a "live 
attenuated" approach, which uses a version of attenuated live ZIKV. 
 
Management of ZIKV infection 
Zika virus infection typically results in a relatively mild and self-limiting clinical 
illness. With the lack of specific treatment, infected individuals should be given 
adequate rest and hydration, and fever reduction using paracetamol rather than 
aspirin and non-steroidal anti-inflammatory drugs (NSAIDs). 
ZIKA-infected people should avoid mosquito bites, abstain from unprotected 
sex, delay pregnancy and not donate blood (WHO, CDC, 2016). 
ZIKV may be present in the saliva but there is as yet no reliable evidence to 
support ZIKV transmission via this body fluid. Transmission in the healthcare 
setting, including oral health, should be effectively prevented using standard 






ZIKV is a new emerging viral infection with global health repercussions. There is 
strong scientific consensus that ZIKV is the cause of microcephaly, Guillain-
Barré syndrome and some other neurological disorders. Additional surveillance 
and research studies are needed to improve our understanding of this disease, 
including the potential epidemiologic and clinical consequences of ZIKV co-
circulation with other flaviviruses. The risk of transmission in the healthcare 








1- Barzon L, Pacenti M, Berto A, Sinigaglia A, Franchin E, Lavezzo E, 
Brugnaro P, Palù G (2016). Isolation of infectious Zika virus from saliva and 
prolonged viral RNA shedding in a traveller returning from the Dominican 
Republic to Italy. Euro Surveill. 2016;21(10).  
2- Besnard M, Lastère S, Teissier A, Cao-Lormeau VM, Musso D (2014). 
Evidence of perinatal transmission of Zika virus, French Polynesia, December 
2013 and February 2014. Euro Surveill 19:pii=20751. 
3- Brasil P, Pereira JP Jr, Raja Gabaglia C, Damasceno L, Wakimoto M, 
Ribeiro Nogueira RM, Carvalho de Sequeira P, Machado Siqueira A, Abreu de 
Carvalho LM, Cotrim da Cunha D, Calvet GA, Neves ES, Moreira ME, 
Rodrigues Baião AE, Nassar de Carvalho PR, Janzen C, Valderramos SG, 
Cherry JD, Bispo de Filippis AM, Nielsen-Saines K (2016). Zika Virus Infection 
in Pregnant Women in Rio de Janeiro - Preliminary Report. N Eng J Med (in 
press). Doi: 10.1056/NEJMoa1602412. 
4- Butler D (2015). Microcephaly surge in doubt. Nature 530: 13–14. 
5- Cao-Lormeau VM, Blake A, Mons S, Lastère S, Roche C, Vanhomwegen 
J, Dub T, Baudouin L, Teissier A, Larre P, Vial AL, Decam C, Choumet V, 
Halstead SK, Willison HJ, Musset L, Manuguerra JC, Despres P, Fournier E, 
Mallet HP, Musso D, Fontanet A, Neil J, Ghawché F (2016). Guillain-Barré 
Syndrome outbreak associated with Zika virus infection in French Polynesia: a 
case-control study. Lancet 6736: 562-66. Doi: 10.1016/S0140-6736(16)00562. 
6-  Carteaux G, Maquart M, Bedet A, Contou D, Brugières P, Fourati S,  
Langavant LC, Broucker T, Brun-Buisson C, Leparc-Goffart I, Dessap AM 
(2016). Zika Virus Associated with Meningoencephalitis. Doi: 
10.1056/NEJMc1602964.  
7- de Paula Freitas B, de Oliveira Dias JR, Prazeres J, Sacramento GA, Ko 
AI, Maia M, Belfort R Jr (2016). Ocularfindings in infants with microcephaly 
associated with presumed Zika Virus congenital infection in Salvador, Brazil. 




8- D'Ortenzio E, Matheron S, de Lamballerie X, Hubert B, Piorkowski G, 
Maquart M, Descamps D, Damond F, Yazdanpanah Y, Leparc-Goffart I. 
Evidence of Sexual (2016) Transmission of Zika Virus. N Engl J Med. [Epub 
ahead of print] DOI: 10.1056/NEJMc1604449 PubMed PMID: 27074370. 
9- Duffy MR, Thane Hancock W, Kool JL, Lanciotti Robert S, Pretrick M,  
Marfel M, Holzbauer S, Dubray C,  Guillaumot L,  Griggs A, Bel M, Lambert AJ,  
Laven J,  Kosoy O, Panella A, Biggerstaff BJ, Fischer M, Hayes EB (2009). Zika 
Virus Outbreak on Yap Island, Federated States of Micronesia. N Engl J Med 
360:2536-43. 
10- Dupont-Rouzeyrol M, O’Connor O, Calvez E, Gourinat AC (2015). 
Detection of Zika Virus in Urine. Emerg Infect Dis 21: 84-86. Doi: 
10.3201/eid.140894.  
11- Dupont-Rouzeyrol M, Biron A, O’Connor O, Huguon E, Descloux E 
(2016). Infectious Zika viral particle in breastmilk. Lancet Mar 
12;387(10023):1051. doi: 10.1016/S0140-6736(16)00624-3. Epub 2016 Mar 2. 
12- Faye O, Freire CCM, Iamarino A, Faye O, Oliveira JVC, Diallo M, Zanotto 
PMA, Sall AA (2014). Molecular Evolution of Zika Virus during Its Emergence in 
the 20th Century. PLoS Negl Trop Dis 8: e2636. 
Doi:10.1371/journal.pntd.0002636. 
13- Foy BD, Kobylinski KC, Chilson Foy JL, Blitvich BJ, Travassos da Rosa 
A, Haddow AD, Lanciotti RS, Tesh RB (2011). Probable non-vector-borne 
transmission of Zika virus, Colorado, USA. Emerg Infect Dis 17: 880-2 
14- Garcez PP, Loiola EC, Madeiro da Costa R, Higa LM, Trindade P, 
Delvecchio R, Nascimento JM, Brindeiro R, Tanuri A, Rehen SK (2016). Zika 
virus impairs growth in human neurospheres and brain organoids.Science (in 
press).   
15- Haddow AD, Schuh AJ, Yasuda CY, Kasper MR, Heang V (2012). 
Genetic Characterization of Zika Virus Strains: Geographic Expansion of the 
Asian Lineage. PLoS Negl Trop Dis 6: e1477. 
Doi:10.1371/journal.pntd.0001477. 
16- Kindhauser MK, Allen T, Frank V, Santhana RS & Dye C (2016). Zika: 
the origin and spread of a mosquito-borne virus [Submitted]. Bull World Health 
Organ E-pub: 9 Feb 2016. doi: http://dx.doi.org/10.2471/BLT.16.171082 
13 
 
17- Kutsuna S, Kato Y, Takasaki T, Moi ML, Kotaki A, Uemura H, Matono T, 
Fujiya Y, Mawatari M, Takeshita N, Hayakawa K, Kanagawa S, Ohmagari N 
(2014). Two cases of Zika fever imported from French Polynesia to Japan, 
December 2013 to January 2014. Euro Surveill. 19: pii=20683.  
18- Lucchese G, Kanduc D (2016).Zika virus and autoimmunity: From 
microcephaly to Guillain-Barré syndrome, and beyond. Autoimmun Rev.  Mar 
25. pii: S1568-9972(16)30077-5. doi: 10.1016/j.autrev.2016.03.020. [Epub 
ahead of print] 
19- Miranda-Filho Dde B, Martelli CM, Ximenes RA et al (2016). Initial 
description of the presumed congenital Zika syndrome. Am J Public Health 
Apr;106(4):598-600. doi: 10.2105/AJPH.2016.303115. 
20- Musso D, Nhan T, Robin E, Roche C, Bierlaire D, Zisou K, Shan Yan A, 
Cao-Lormeau VM, Broult J (2014). Potential for Zika virus transmission through 
blood transfusion demonstrated during an outbreak in French Polynesia, 
November 2013 to February 2014. Euro Surveill. 9:pii=20761. 
21- Musso D, Roche C, Nhan TX, Robin E, Teissier A, Cao-Lormeau VM 
(2015). Detection of Zika vírus in saliva. Clin Virol 68: 53-55. 
Doi:10.1016/j.jcv.2015.04.021. Epub 2015 Apr 29. 
22- Oehler E, Watrin L, Larre P, Leparc-Goffart I, Lastère S, Valour F, 
Baudouin L, Mallet HP, Musso D, Ghawche F (2014). Zika virus infection 
complicated by Guillain-Barré syndrome – case report, French Polynesia, 
December 2013. Euro Surveill 19: pii=20720. 
23- Oliveira Melo AS, Malinger G, Ximenes R, Szejnfeld PO, Alves Sampaio 
S, Bispo de Filippis AM (2016). Zika virus intrauterine infection causes fetal 
brain abnormality and microcephaly: tip of the iceberg? Ultrasound Obstet 
Gynecol 47: 6-7. Doi: 10.1002/uog.15831. 
24- Rasmussen SA, Jamieson DJ, Honein MA, Petersen LR. Zika Virus and 
Birth Defects - Reviewing the Evidence for Causality. N Engl J Med. 2016 Apr 
13. [Epub ahead of print] PubMed PMID: 27074377. 
25- Scully C, Robinson A (2016). Check before you traval: Zika virus – 
another emerging global health threat. Br Dent J. 11;220(5):265-7. 
26- Shakib K (2016). Epidemic of Zika virus and maxillofacial surgery. Br J 
Oral Maxillofac Surg. 2016 Feb 19. pii: S0266-4356(16)00058-9. doi: 
10.1016/j.bjoms.2016.02.001. [Epub ahead of print].  
14 
 
27- Tappe D, Rissland J, Gabriel M, Emmerich P, Günther S, Held G, Smola 
S, Schmidt-Chanasit J (2014). First case of laboratory-confirmed Zika virus 
infection imported into Europe, November 2013. Euro Surveill. 19: pii=20685. 
28- Willison HJ, Jacobs BC, van Doorn PA (2016). Guillain-Barré syndrome. 
Lancet. Feb 29. pii: S0140-6736(16)00339-1. doi: 10.1016/S0140-











Criterion Evidence Criterion 
Met? 
1 Proven exposure to 
the agent at one or 
more critical times 
during prenatal 
development 
On the basis of case reports, case series and 
epidemiologic studies of microcephaly that are 
associated with laboratory-confirmed or 
presumed ZIKV infection, the timing of ZIKV 
virus infection associated with severe 
microcephaly and intracranial calcifications 
appears to be in the late first or early second 
trimester 
Yes 
2 Consistent findings 
by 2 ≥ high-quality 
epidemiologic 




of positive and 
negative bias factors, 
prospective studies if 
possible, and relative 
risk≥6 
On the basis of data from Brazil, temporal and 
geographic association between ZIKV illness 
and cases of microcephaly is strong. Two 
epidemiologic studies have been published. In a 
study in Brazil, that used a prospective cohort 
design, 29% of women with ZIKV infection at 
any time during pregnancy had abnormalities 
on prenatal ultrasonography, some of which 
have not been confirmed postnatally. Ina study 
in French Polynesia, retrospective identification 
of eight cases of microcephaly and the use of 
serologic and statistical data and mathematical 
modeling suggested that 1% of foetuses and 
infants born to women with ZIKV infection 
during the first trimester had microcephaly; the 
risk ratio in this analysis was approximately 50, 
as compared with the baseline prevalence of 
microcephaly. 
No other epidemiologic studies have examined 
this association to date. 
Partially 
3 Careful delineation of 
clinical cases; a 
specific defect or 
syndrome, if present, 
is very helpful 
The phenotype has been well characterised in 
foetuses and infants with presumed congenital 
ZIKV infection, including microcephaly and 
other serious brain anomalies, redundant scalp 
skin, eye findings, arthrogryposis and clubfoot.  
The phenotype in some infants appears to be 
consistent with the foetal brain disruption 
sequence, which has been observed after 
infection with other viral teratogens. 
Yes 
4 Rare environmental 
exposure that is 
associated with rare 
defect 
Reports of foetuses and infants with 
microcephaly who are born to women with brief 
periods of travel to countries with active ZIKV 
transmission are consistent with ZIKV being a 
rare exposure. 
The defect, congenital microcephaly, is rare, 
with a birth prevalence of approximately 6 




data from birth-defects surveillance systems in 
the United States. 
5 Teratogenicity in 
experimental animals 
important but not 
essential 
No results of an animal model with ZIKV 
infection during pregnancy and foetal effects 
have yet been published. 
No 
6 Association should 
make biologic sense 
Findings are similar to those seen after prenatal 
infection with some other viral teratogens (eg 
rubella virus, cytomegalovirus). 
Animal models have shown that ZIKV is 
neurotropic, which supports biologic plausibility. 
Evidence that ZIKV infects neural progenitor 
cells and produces cell death and abnormal 
growth, along with evidence of ZIKV in brains of 
foetuses and infants with microcephaly, on the 
basis of immunohistochemical staining and 
identification of ZIKV RNA and live virus, 
provides biologic plausibility. 
Yes 
7 Proof in an 
experimental system 
that the agent acts in 
an unaltered state 
The criterion applies to a medication or 
chemical exposure, not to infectious agents. 
NA 
* Criteria 1,2 and 3 or criteria 1, 3 and 4 are considered to be essential, whereas criteria 
5,6 and 7 are helpful but not essential. Partial evidence is insufficient to meet a criterion. 


















Table 2. Countries with confirmed local transmission of ZIKV (to April/2016). 
 
North America South America Central America Asia Europe Oceania 
Mexico Brazil Haiti Bangladesh Portugal Papua New Guinea 
Canada Colombia El Salvador Vietnam Italy  
United States Venezuela Panama Philippines France  
 Bolivia Honduras New Caledonia   
 Argentina Martinique Laos   
 French Guiana Puerto Rico    
 Peru Belize    
 Suriname Costa Rica    
 Chile Republic of 
Trinidad and 
Tobago 
   
  Aruba    
  Curacao    
  Saint Maarten    
  U.S. Virgin 
Islands 
   
  Barbados    
  Dominican 
Republic 
   
  Nicaragua    
  Jamaica    
  Bonaire    
  Saint Vincent 
and the 
Grenadines 
   
  Cuba    
  Dominica    
  Saint Lucia    
18 
 
Figure 1. The ZIKV virus, which is commonly found in parts of Africa and South 
East Asia spread to Latin America via French Polynesia. Last year more than 
1.5 million people in South America became infected, before the virus spread to 
the Caribbean, Mexico and Texas towards the end of 2015 (Published: 13:53 
GMT, 5 February 2016, Daily Mail)  
 
